Malaysian Biotech Expects Huge Boost With Tamiflu Generic Contract
This article was originally published in PharmAsia News
Malaysia's CCM Duopharma Biotech expects to see a huge increase in earnings this year due to a government contract to produce a generic version of Roche's Tamiflu (oseltamivir)
You may also be interested in...
There is speculation that it is the end of the road for abicipar pegol but Allergan has declined to say whether this is the case for the product that has been in development for wet AMD.
In the EU, voices calling for a postponement of the IVD Regulation’s 2022 enforcement date are growing louder.
After talking with the FDA, Atox will file an NDA for its necrotizing soft tissue infections therapy despite missing primary endpoints in a pivotal trial, the biotech’s CEO tells Scrip.